Androgen deprivation therapy

The results from the final analysis of the phase 3 TITAN study, which has demonstrated the continued statistically significant benefit...

Castration-resistant prostate cancer ( CRPC ) is defined as disease progression during ADT ( androgen deprivation therapy ), with serum...

The phase III SPARTAN study evaluated Apalutamide ( Erleada ) vs Placebo in patients with non-metastatic castration-resistant prostate cancer (...

Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate...

The American Cancer Society estimates that in 2020, there will have been more than 190,000 cases of prostate cancer in...

The Food and Drug Administration ( FDA ) has approved the first oral gonadotropin-releasing hormone ( GnRH ) receptor antagonist,...

The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...

SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and...

Darolutamide ( Nubeqa ) is a structurally distinct androgen receptor inhibitor with a favorable safety profile, approved for treating men...

Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...

The European Commission ( EC ) has granted marketing authorisation for Erleada ( Apalutamide ), a next generation oral androgen...

Results from the phase 3 TITAN study were presented in an oral session at the American Society of Clinical...

For patients with prostate cancer, treating the disease with androgen deprivation therapy ( ADT ) is linked to a...

Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic...

Radium-223 dichloride ( Ra-233; Xofigo ), a bone targeting alpha radiopharmaceutical, and Enzalutamide ( Xtandi ), are approved for metastatic...

The PROSPER trial has shown a clinically and statistically significant improvement in metastasis-free survival ( hazard ratio, HR=0.292 [ 95%...

The results from the phase 3 PROSPER trial in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CRPC...

New findings were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium ( ASCO GU ) in San...

A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy (...

Data from the pivotal phase 3 LATITUDE clinical trial showed Abiraterone acetate ( Zytiga ) plus Prednisone, in combination with...

Successivi →

MedTV

Resistenza batterica agli antibiotici
Basi per il corretto impiego degli antibiotici in Medicina Generale
Tumore al polmone: valutazione geriatrica multidimensionale
Depressione maggiore: rischio di epatotossicità con Agomelatina
Epatite C: gravi reazioni cutanee dopo trattamento con Telaprevir, PegInterferone alfa e Ribavirina
Impiego estetico della Tossina botulinica: importanti informazioni di sicurezza
Fibrillazione atriale non-valvolare: prevenzione dell'ictus con Rivaroxaban
Anticoagulanti: i limiti del Warfarin
Cinryze nel trattamento dell'angioedema ereditario
Trattamento dei coaguli ematici: Xarelto raccomandato dal NICE

MedVideo

Ruolo dell'immunoterapia nella prima linea di terapia del NSCLC
Resistenza batterica agli antibiotici
Basi per il corretto impiego degli antibiotici in Medicina Generale
Prospettive nella terapia di prima linea del carcinoma polmonare non a piccole cellule non-oncogene-addicted
Covid-19 e neoplasie ematologiche
Carcinoma polmonare a piccole cellule: stato dell'arte e prospettive future
Trattamento della macroglobulinemia di Waldenstrom
Trattamento del linfoma mantellare alla recidiva
Immunoterapia: carcinoma polmonare non a piccole cellule, trattamento di seconda linea
Casi clinici in OncoPneumologia: Lung mass

Cerca